RFP en es it fr

RFP Brand names, RFP Analogs

RFP Brand Names Mixture

  • Rifater (Isoniazid + Pyrazinaamide + Rifampin)
  • Rifamate (Rifampin + Isoniazid)

RFP Chemical_Formula


RFP RX_link


RFP fda sheet


RFP msds (material safety sheet)


RFP Synthesis Reference

No information avaliable

RFP Molecular Weight

822.94 g/mol

RFP Melting Point

183 oC

RFP H2O Solubility

1.4 mg/mL

RFP State




RFP Dosage Forms


RFP Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.

RFP Pharmacology

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

RFP Absorption

Well absorbed from gastrointestinal tract.

RFP side effects and Toxicity

LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness

RFP Patient Information

The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this. Soft contact lenses may be permanently stained. The patients should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water. Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints. Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.

RFP Organisms Affected

Mycobacteria and a variety of other gram negative and gram postivie bacteria